Rhodamine 123 efflux modulation in the presence of low or high serum from CD56+ hematopoietic cells or CD34+ leukemic blasts by B9309-068, a newly designed pyridine derivative

Cancer Letters

Volumn 129, Issue 2, 1998, Pages 157-163

  Beck, James Friedrich ^a   Buchholz, Frank ^a   Ulrich, Wolf Rüdiger ^b   Boer, Rainer ^b   Sanders, Karl Heinrich ^b   Niethammer, Dietrich ^a   Gekeler, Volker ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b ALTANA PHARMA AG   (Germany)

Author keywords

B9309 068; CD56+ cells; Chemosensitizers; Dexniguldipine HCl; Dexverapamil HCl; GF120918; Human serum; Leukemic blasts; MDR1 P glycoprotein; Multidrug resistance; PerCP conjugated monoclonal antibodies; Rhodamine 123 efflux; SDZ PSC 833

Indexed keywords

ACRIDONE DERIVATIVE; ANTINEOPLASTIC AGENT; B 9309 068; CD34 ANTIGEN; CD56 ANTIGEN; CHLOROPHYLL; DEXNIGULDIPINE; DEXVERAPAMIL; ELACRIDAR; MONOCLONAL ANTIBODY; PYRIDINE DERIVATIVE; RHODAMINE 123; UNCLASSIFIED DRUG; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLAST CELL; CONTROLLED STUDY; DRUG RESISTANCE; DRUG TRANSPORT; FETAL CALF SERUM; FLOW CYTOMETRY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; SERUM; TARGET CELL;

EID: 0032547022     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00094-9     Document Type: Article

References (26)

1. Beck J., Gekeler V., Ringger M., Handgretinger R., Niethammer D. Rhodamine 123-efflux from hematopoietic subpopulations and leukaemic blast populations marked by PerCP-conjugated monoclonal antibodies. Cancer Lett. 99:1996;197-207.
2. Beck J., Handgretinger R., Dopfer R., Klingebiel T., Niethammer D., Gekeler V. Expression of MDR1, MRP, topoisomerase IIα/β, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. Br. J. Haematol. 89:1995;356-363.
3. Beck J., Handgretinger R., Klingebiel T., Dopfer R., Schaich M., Ehninger G., Niethammer D., Gekeler V. Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML. Leukemia. 10:1996;426-433.
4. Boer R., Gekeler V. Chemosensitizers in tumor therapy: new compounds promise better efficacy. Drugs Future. 20:1995;499-509.
5. Boesch D., Gaveriaux C., Jachez B., Pourtier Manzanedo A., Bollinger P., Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res. 51:1991;4226-4233.
6. Boesch D., Muller K., Pourtier Manzanedo A., Loor F. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp. Cell Res. 196:1991;26-32.
7. Chaudhary P.M., Mechetner E.B., Roninson I.B. Expression and activity of the multidrug resistance p-glycoprotein in human peripheral blood lymphocytes. Blood. 80:1992;2735-2739.
8. Chirgwin J.M., Przybyla A.E., MacDonald R.J., Rutter W.J. Isolation of biological active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 18:1979;5294-5299.
9. Den Ouden D., van den Heuvel M., Schoester M., van Rens G., Sonneveld X. In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells. Leukemia. 10:1996;1930-1936.
10. Gekeler V., Boer R., Ise W., Sanders K.H., Schächtele C., Beck J. The specific bisindolylmaleimide PKC-inhibitor GF 109203X efficiently modulates MRP-associated multiple drug resistance. Biochem. Biophys. Res. Commun. 206:1995;119-126.
11. Germann U.A. P-Glycoprotein - a mediator of multidrug resistance in tumour cells. Eur. J. Cancer. 32A:1996;927-944.
12. Häussermann K., Benz B., Gekeler V., Schumacher K., Eichelbaum M. Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines. Eur. J. Clin. Pharmacol. 40:1991;53-59.
13. Hofmann J., Gekeler V., Ise W., Noller A., Mitterdorfer J., Hofer S., Utz I., Gotwald M., Boer R., Glossmann H., Grunicke H. Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance. Biochem. Pharmacol. 49:1995;603-609.
14. Hyafil F., Vergely C., Du Vignaud P., Grand Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53:1993;4595-4602.
15. Jedlitschky G., Leier I., Buchholz U., Center M., Keppler D. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res. 54:1994;4833-4836.
16. Kiue A., Sano T., Suzuki K., Inada H., Okumura M., Kikuchi J., Sato S., Kohno K., Kuwano M. Activities of newly synthesized dihydropyridines in overcoming of vincristine resistance, calcium antagonism, and inhibition of photoaffinity labeling of P-glycoprotein in rodents. Cancer Res. 50:1990;310-317.
17. - cases. Blood. 86:1995;2329-2342.
18. Loe D.W., Deeley R.G., Cole S.P. Biology of the multidrug resistance-associated protein, MRP. Eur. J. Cancer. 32A:1996;945-957.
19. 3H] vinblastine binding to P-glycoprotein of CCRF ADR 5000 cells. Eur. J. Pharmacol. 288:1994;105-114.
20. Marie J.P., Zhou D.C., Gurbuxani S., Legrand O., Zittoun R. MDR1/P-glycoprotein in haematological neoplasms. Eur. J. Cancer. 32A:1996;1034-1038.
21. 2 (3) is not a substrate for multidrug resistance protein (MRP)-mediated drug extrusion. Proc. Annu. Meet. Am. Assoc. Cancer Res. 37:1996;311.
22. Schuurhuis G.J., Broxterman H.J., Ossenkoppele G.J., Baak J.P.A., Eekman C.A., Kuiper C.M., Feller N., van Heijningen T.H.M., Klumper E., Pieters R., Lankelma J., Pinedo H.M. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-β-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin. Cancer Res. 1:1995;81-93.
23. Van-de-Vrie W., Schellens J.H., Loss W.J., Kolker H.J., Verwey J., Stoter G., Durante N.M., Eggermont A.M. Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rat colon carcinoma model. J. Cancer Res. Clin. Oncol. 122:1996;403-408.
24. Wilisch A., Noller A., Handgretinger R., Weger S., Nuessler V., Niethammer D., Probst H., Gekeler V. Mdr1/P-glycoprotein expression in natural killer (NK) cells enriched from peripheral or umbilical cord blood. Cancer Lett. 699:1993;139-148.
25. Witherspoon S.M., Emerson D.L., Kerr B.M., Lloyd T.L., Dalton W.S., Wissel P.S. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin. Cancer Res. 2:1996;7-12.
26. Zhou D.-C., Simonin G., Faussat A.-M., Zittoun R., Marie J.-P. Effect of the multidrug inhibitor GG918 on drug sensitivity of human leukemic cells. Leukemia. 11:1997;1516-1522.